CINGW — what changed in the latest 10-Q
A section-by-section comparison of CINGW's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-13 vs the prior 10-Q · 2026-05-14
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +20 | −21 | ~36 | 55 |
| Market risk (Item 3) | Text added/removed | +20 | −21 | ~35 | 55 |
| Controls & procedures | Text added/removed | +20 | −21 | ~35 | 55 |
| Legal proceedings | Text added/removed | +20 | −21 | ~35 | 55 |
| Risk factors | Text added/removed | +20 | −21 | ~35 | 55 |
| Other information | Text added/removed | +20 | −21 | ~34 | 55 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-13
● our ability to identify, recruit, and retain key personnel;
Long-term portion of operating lease liability (131,767) 1,223,587
Proceeds from the issuance of common stock and common stock purchase warrants, net of fees 31,050,164 6,102,756
Cingulate Inc. (Cingulate, or the Company), a Delaware corporation, is a biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus …
The Company submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) on July 31, 2025 for lead asset CTx-1301 and received confirmation of acceptance of the NDA in early October 2025 with a Prescription Drug User Fee Act (PDUFA) target action date of May 31, 2026. On J…
Text removed vs the prior filing · source: 10-Q · 2026-05-14
Net loss per share of common stock, basic and diluted $(0.95) $(1.06)
Weighted average number of shares used in computing net loss per share of common stock, basic and diluted 9,777,786 3,646,893
Shares Amount Shares Amount Paid-in-Capital Deficit Income Equity
Common Stock Preferred Stock Additional Accumulated Other Comprehensive Stockholders’
Shares Amount Shares Amount Paid-in-Capital Deficit Income Equity
Market risk (Item 3)
Text added vs the prior filing · source: 10-Q · 2026-08-13
● our ability to identify, recruit, and retain key personnel;
Long-term portion of operating lease liability (131,767) 1,223,587
Proceeds from the issuance of common stock and common stock purchase warrants, net of fees 31,050,164 6,102,756
Cingulate Inc. (Cingulate, or the Company), a Delaware corporation, is a biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus …
The Company submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) on July 31, 2025 for lead asset CTx-1301 and received confirmation of acceptance of the NDA in early October 2025 with a Prescription Drug User Fee Act (PDUFA) target action date of May 31, 2026. On J…
Text removed vs the prior filing · source: 10-Q · 2026-05-14
Net loss per share of common stock, basic and diluted $(0.95) $(1.06)
Weighted average number of shares used in computing net loss per share of common stock, basic and diluted 9,777,786 3,646,893
Shares Amount Shares Amount Paid-in-Capital Deficit Income Equity
Common Stock Preferred Stock Additional Accumulated Other Comprehensive Stockholders’
Shares Amount Shares Amount Paid-in-Capital Deficit Income Equity
Controls & procedures
Text added vs the prior filing · source: 10-Q · 2026-08-13
● our ability to identify, recruit, and retain key personnel;
Long-term portion of operating lease liability (131,767) 1,223,587
Proceeds from the issuance of common stock and common stock purchase warrants, net of fees 31,050,164 6,102,756
Cingulate Inc. (Cingulate, or the Company), a Delaware corporation, is a biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus …
The Company submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) on July 31, 2025 for lead asset CTx-1301 and received confirmation of acceptance of the NDA in early October 2025 with a Prescription Drug User Fee Act (PDUFA) target action date of May 31, 2026. On J…
Text removed vs the prior filing · source: 10-Q · 2026-05-14
Net loss per share of common stock, basic and diluted $(0.95) $(1.06)
Weighted average number of shares used in computing net loss per share of common stock, basic and diluted 9,777,786 3,646,893
Shares Amount Shares Amount Paid-in-Capital Deficit Income Equity
Common Stock Preferred Stock Additional Accumulated Other Comprehensive Stockholders’
Shares Amount Shares Amount Paid-in-Capital Deficit Income Equity
Legal proceedings
Text added vs the prior filing · source: 10-Q · 2026-08-13
● our ability to identify, recruit, and retain key personnel;
Long-term portion of operating lease liability (131,767) 1,223,587
Proceeds from the issuance of common stock and common stock purchase warrants, net of fees 31,050,164 6,102,756
Cingulate Inc. (Cingulate, or the Company), a Delaware corporation, is a biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus …
The Company submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) on July 31, 2025 for lead asset CTx-1301 and received confirmation of acceptance of the NDA in early October 2025 with a Prescription Drug User Fee Act (PDUFA) target action date of May 31, 2026. On J…
Text removed vs the prior filing · source: 10-Q · 2026-05-14
Net loss per share of common stock, basic and diluted $(0.95) $(1.06)
Weighted average number of shares used in computing net loss per share of common stock, basic and diluted 9,777,786 3,646,893
Shares Amount Shares Amount Paid-in-Capital Deficit Income Equity
Common Stock Preferred Stock Additional Accumulated Other Comprehensive Stockholders’
Shares Amount Shares Amount Paid-in-Capital Deficit Income Equity
Risk factors
Text added vs the prior filing · source: 10-Q · 2026-08-13
● our ability to identify, recruit, and retain key personnel;
Long-term portion of operating lease liability (131,767) 1,223,587
Proceeds from the issuance of common stock and common stock purchase warrants, net of fees 31,050,164 6,102,756
Cingulate Inc. (Cingulate, or the Company), a Delaware corporation, is a biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus …
The Company submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) on July 31, 2025 for lead asset CTx-1301 and received confirmation of acceptance of the NDA in early October 2025 with a Prescription Drug User Fee Act (PDUFA) target action date of May 31, 2026. On J…
Text removed vs the prior filing · source: 10-Q · 2026-05-14
Net loss per share of common stock, basic and diluted $(0.95) $(1.06)
Weighted average number of shares used in computing net loss per share of common stock, basic and diluted 9,777,786 3,646,893
Shares Amount Shares Amount Paid-in-Capital Deficit Income Equity
Common Stock Preferred Stock Additional Accumulated Other Comprehensive Stockholders’
Shares Amount Shares Amount Paid-in-Capital Deficit Income Equity
Other information
Text added vs the prior filing · source: 10-Q · 2026-08-13
● our ability to identify, recruit, and retain key personnel;
Long-term portion of operating lease liability (131,767) 1,223,587
Proceeds from the issuance of common stock and common stock purchase warrants, net of fees 31,050,164 6,102,756
Cingulate Inc. (Cingulate, or the Company), a Delaware corporation, is a biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus …
The Company submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) on July 31, 2025 for lead asset CTx-1301 and received confirmation of acceptance of the NDA in early October 2025 with a Prescription Drug User Fee Act (PDUFA) target action date of May 31, 2026. On J…
Text removed vs the prior filing · source: 10-Q · 2026-05-14
Net loss per share of common stock, basic and diluted $(0.95) $(1.06)
Weighted average number of shares used in computing net loss per share of common stock, basic and diluted 9,777,786 3,646,893
Shares Amount Shares Amount Paid-in-Capital Deficit Income Equity
Common Stock Preferred Stock Additional Accumulated Other Comprehensive Stockholders’
Shares Amount Shares Amount Paid-in-Capital Deficit Income Equity
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice